An intelligent paper-based microfluidic platform based on "controllable grafting and azide-coated layer" nanozyme@molecular imprinting probes is used for BTMs detection and OP screening

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500114946

Enrollment

Unknown

Registered

2025-12-19

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Healthy group:No intervention

Osteoporosis group:No intervention

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Both individuals with normal bone density and those with reduced bone density can be included in the study.

Exclusion criteria

Exclusion criteria: All the samples in this study excluded patients with cancer, liver disease, kidney disease, metabolic disorders or hereditary bone diseases, as well as those who were using drugs that might affect bone metabolism.

Design outcomes

Primary

Measure	Time frame
PINP;ß-CTX;N-Mid Oc;BALP;TRAP-5b;PTH;25-OHVD;	—

Countries

Chian

Contacts

Public ContactJiawei Li

Chongqing University Three Gorges Hospital

562470526@qq.com+86 187 2585 0941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026